Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>HSBC Research Continues to Favor Mainland CDMO Industry, Recommends Buying PHARMARON/ WUXI XDC
Recommend 4 Positive 5 Negative 2 |
||||
|
||||
|
HSBC Global Research report mentioned that the US had recently passed the "Biosecure Act", prohibiting federal agencies from procuring, renewing, or extending contracts related to "biotechnology companies of concern". In the broker's view, the Act may wreak short-term market fluctuations, but it remains optimistic about the long-term growth of China's CDMO industry. Companies can manage risks by diversifying business regions, expanding non-US clientele, and avoiding direct contracts. The earnings visibility of market leaders remains intact, said HSBC Global Research, and the Act allows a five-year exemption period for already signed contracts, implying limited short-term operational impact. Regarding stocks, the broker preferred PHARMARON (03759.HK) and WUXI XDC (02268.HK), both rated as Buy, with target prices of HKD28.1 and HKD90 respectively. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
